Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed ...

The S&P 500 ended down on Wednesday after a hotter-than-expected U.S. inflation reading added to worries that the Federal ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...

The S&P 500 slipped after a strong U.S. inflation report dashed hopes for rate cuts. CVS Health and Gilead Sciences rose on positive earnings, contrasting Nvidia and Amazon's declines. President Trump ...

Investors led by Elon Musk offer $97.4 billion for OpenAI. Sam Altman replies: 'No thank you.' ...

The S&P 500 dipped amid news of higher-than-expected U.S. inflation, dampening hopes for a Federal Reserve rate cut. Despite ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and ...

Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...